TFRC

Transferrin receptor protein 1

Score: 0.579 Price: $0.58 Medium Druggability Status: active Wiki: TFRC

🧠 Neurodegeneration

HYPOTHESES

3

PAPERS

31

KG EDGES

151

DEBATES

1

3D Protein Structure

🧬 TFRC — PDB 1CX8 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Medium

Score: 0.47

Clinical Stage

Approved

Target Class

Receptor

Safety

0.50

Druggability Analysis

Drug Development0.60

Structural Tractability0.85

Target Class0.70

Safety Profile0.50

Key Metrics

PDB Structures:

19

Known Drugs:

2

Approved:

0

In Clinical Trials:

0

Drug Pipeline (2 compounds)

Druggability Rationale: TFRC is highly druggable (0.80 score) due to its well-characterized receptor structure with 19 PDB entries at high resolution (1.85 Å), enabling rational design of both monoclonal antibodies and small-molecule iron chelators. The target's established mechanism of action with approved drugs (Deferasirox) and ongoing clinical-stage antibody therapies demonstrates clear validation for therapeutic intervention.

Mechanism: Monoclonal antibodies targeting receptor or iron chelation affecting iron uptake

Drug Pipeline (2 compounds)

Known Drugs:

Deferasirox (Approved) — Iron chelation

Anti-TfR1 antibodies (Clinical trials) — Drug delivery

Structural Data:

PDB (19) ✓AlphaFold ✓Cryo-EM ✓

1SUV 2NSU 3S9L 3S9M 3S9N+14 more

UniProt: G3V0E5

🧬 3D Protein Structure

🧬 TFRC — PDB 1CX8 Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

TFRC selectivity is generally favorable as the transferrin receptor isoform is the primary iron uptake mechanism in most tissues; however, off-target effects on systemic iron homeostasis and potential impacts on erythropoiesis must be carefully monitored. Monoclonal antibodies offer superior selectivity compared to broad iron chelators, reducing systemic iron dysregulation.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

0

Completed

6

Total Enrollment

218

By Phase

PHASE1: 1 · PHASE2: 6 · PHASE4: 1

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec Completed

PHASE2 NCT00879242 n=20

Beta Thalassemia Transfusion Dependent

Interventions: Deferasirox

Sponsor: Novartis Pharmaceuticals | Started: 2009-02

Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardia Completed

PHASE2 NCT01254227 n=60

Cardiac Iron Overload

Interventions: Deferasirox and Deferoxamine

Sponsor: Novartis Pharmaceuticals | Started: 2011-01

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed

PHASE2 NCT01273766 n=16

Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Re, Adult Acute Myeloid Leukemia in Remissio

Interventions: deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay

Sponsor: Wake Forest University Health Sciences | Started: 2011-01

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed

PHASE2 NCT00419770 n=20

Mucormycosis

Interventions: deferasirox, Placebo, Liposomal amphotericin B

Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA | Started: 2007-10

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload Completed

PHASE2 NCT00379483 n=66

Transfusional Iron Overload

Interventions: Deferasirox

Sponsor: Novartis Pharmaceuticals | Started: 2002-07

Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers Completed

PHASE1 NCT00419172 n=22

Healthy

Interventions: Deferasirox, Rifampicin

Sponsor: Novartis | Started: 2007-01

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study Terminated

PHASE4 NCT01326845 n=12

Myelodysplastic Syndrome, Transfusional Iron Overload

Interventions: Deferasirox

Sponsor: Novartis Pharmaceuticals | Started: 2011-12

Exjade-Early-Trial Terminated

PHASE2 NCT01058369 n=2

Myelodysplastic Syndromes

Interventions: Deferasirox (Novartis Pharma)

Sponsor: University of Erlangen-Nürnberg Medical School | Started: 2010-04

Linked Hypotheses (2)

Blood-Brain Barrier SPM Shuttle System0.533

Transferrin-Alectinib Conjugation Enhances Blood-Brain Barrier Transport via Transferrin Receptor-Me0.406

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

associated with (8)

TFRC→neurodegenerationLAMP2→TFRCTFRC→PPP1CBTFRC→MTORTFRC→BID

▸ Show 3 more

TFRC→BADMTOR→TFRCTFRC→LAMP2

co discussed (8)

BMAL1→TFRCALOX15→TFRCCLOCK→TFRCTFRC→GPR37TFRC→CMKLR1

▸ Show 3 more

TFRC→ALOX12TFRC→ALOX5BCL2L1→TFRC

expressed in (1)

interacts with (2)

JUN→TFRCGBA1→TFRC

therapeutic target (1)

Debate History (1)

Should TFRC (Transferrin receptor protein 1) be prioritized as a therapeutic tar2026-04-21